• Pay My Bill
  • Careers
  • Donate
  • +1 (844) 401-0111

Famed Rhode Island Alzheimer’s Researcher Addresses Global Conference with 6 Goals for Ending Alzheimer’s

Prime Minster Rutte and Health Minister Held

(From left to right: Professor Charlotte Teunissen, Sir Philip Scheltens, Prime Minister Mark Rutte, Health Minister Connie Held, Professor Mia Kivipelto, Professor Wiesje van der Flier, and Dr. Stephen Salloway)

 

Founding director of the Memory and Aging Program (MAP) at Butler Hospital, Dr. Stephen Salloway, gave the keynote speech to open the “Defeating Dementia” conference on October 2, 2023. This global conference of government and health leaders addressed the challenges dementia poses to society and the swift progress that can be made in care delivery, diagnosis, and drug discovery through unified, concrete actions and public investment in dementia research.

The meeting in Amsterdam emphasized discovery science, implementation of advances and new technologies, and dignity and inclusion for people living with dementia. A proclamation, signed by more than 30 countries, with a commitment to increase research funding and collaboration, was announced at the end of the meeting.

Rhode Island’s Representation at the “Defeating Dementia” Conference
As mentioned, MAP’s founding director, Stephen Salloway, MD, MS, and Professor of Psychiatry and Human Behavior and Neurology at the Warren Alpert Medical School of Brown University, provided the plenary keynote address to open the conference.

In his address to global policymakers, patient advocates, and dementia experts, Dr. Salloway shared his thoughts on what he believes are the six (6) great challenges to addressing the increasing epidemic of Alzheimer’s around the globe today.

Those include:

  1. Instituting steps to ensure safe administration and monitoring for clinical use of new AD medications.
  2. Additional research into combination therapies that could enhance treatment effects.
  3. Tests to guide clinicians in measuring the efficacy of treatment in each individual, and to gauge when treatment can be stopped or when it may need to be restarted.
  4. Overcoming barriers to provide broad access to these new tests and treatments, specifically plans to move research and clinical treatment out of the hospital setting and into the community to make it more accessible for everyone.
  5. Strategies to enable treatment before the development of symptoms; specifically, ways to identify individuals who have amyloid and tau build-up in the brain but who are not yet exhibiting any symptoms of dementia.
  6. Concerted, and coordinated efforts to move preventative lifestyle interventions forward, particularly regarding how they might be combined with disease-modifying treatments for those most at risk.

“We now know that brain changes in Alzheimer's disease begin decades before memory loss. What's most remarkable is that we have new blood tests to measure amyloid and tau that can be used now to pre-screen for the new disease-modifying treatments to identify people who are eligible for clinical trials and for diagnosis in memory clinics,” Dr. Salloway said. “It's not just the medicine, it's the whole package of care that's required. It's very important for health systems who are thinking about this [to understand] there will be some challenges and some change needed in the standard of care… The challenge will be building the infrastructure and workforce to roll these treatments out safely.”

Dr. Salloway also highlighted the major recent advances in understanding AD prevention.

“Equally important is risk modification and prevention,” Dr. Salloway said. “The new biomarkers have helped open a new era of Alzheimer's prevention research and we're also learning that 40% of the risk of dementia may be modifiable through lifestyle interventions such as good heart health, exercise, healthy diets, social and cognitive stimulation.”

More about the “Defeating Dementia” Conference
The conference was hosted by the Ministry of Health, Welfare, and Sport of The Netherlands with the collaboration of the World Dementia Council. Attendees included delegations from six continents, G-20 leaders, and leaders of major global organizations, including the World Health Organization (WHO), World Bank, American Association of Retired Persons (AARP), the Alzheimer’s Association, and other global Alzheimer’s associations.

Maria Carrillo, VP for Research of the Alzheimer’s Association, announced that ALZ-NET, the research network to track the safety and efficacy of disease-modifying treatments, was extending participation in the network to countries around the world.

The Netherlands Health Minister, Connie Held, announced she will be leading a Dutch delegation to China to learn from the Chinese experience with dementia research and care and to build new collaborations. China currently has 280 million people aged 60 and older.

Prime Minister Mark Rutte of the Netherlands delivered the conference’s closing remarks.

About the Memory and Aging Program at Butler Hospital
The Memory & Aging Program (MAP) at Butler Hospital is a worldwide leader in Alzheimer’s disease research and a local Rhode Island partner in the fight against Alzheimer’s and other forms of dementia. An affiliate of The Warren Alpert Medical School of Brown University, MAP has a 25-year history of excellence in Alzheimer’s clinical care, training, and research aimed at developing new and better ways to detect, treat, and someday even prevent Alzheimer’s. Individuals who wish to be considered for participation in current and future research studies and clinical trials conducted at the Memory and Aging Program for the prevention and treatment of Alzheimer’s disease can join the program’s Alzheimer’s Prevention Registry at Butler Hospital online at butler.org/ALZregistry or by calling (401) 455-6402. For more information visit butler.org/memory.